Our findings demonstrate that inhibition of the lncRNA DLEU2/ROR1 pathway may complement the antitumor or anti-metastatic activity by eliminating drug-resistant CSCs or inhibiting tumor cells from acquiring CSC-like characteristics. Here, DLEU2 is linked to neoplasm.